DCVMN COVID-19
COMMITTEE REPORT

DCVMN Annual General Meeting (AGM)
20 – 22 October 2022
Pune, India
Objectives of the COVID-19 Committee

1. Prime COVID-19 vaccine candidates,
2. Disseminate technical information relating to COVID-19 vaccine development
3. Solutions provided by organizations such as CEPI, etc,
4. Assess and share technologies important for COVID vaccine development
5. Develop and support solid bases for statements to support DCVMN dialogue with global stakeholders and in public meetings

Protecting people from global diseases since 2000.

DCVMN
Developing Countries Vaccine Manufacturers Network
Organization of the committee
(June 19th 2020)

Chair : Adriansjah Azhari (Bio Farma, Indonesia)
Co-chair : Raches Ella (Bharat Biotech, India)
Secretary : Apoorv Kumar (Bharat Biotech, India)

Members :
1. Indian Immunologicals, India
2. Panacea, India
3. SII, India
4. BioE, India
5. Pasteur Institute, India
6. Zhifei, China
7. Bravovax, China
8. BCHT, China
9. Innovax, China
10. CNBG, China
11. St Petersburg Scientific Research Institute of Vaccines and Sera, Russia
12. Biomanguinhos, Brazil
13. Singernium, Argentina
14. Bionet Asia, Thailand

Organization of the committee
(As of Feb 10th 2022)

Chair : Adriansjah Azhari (Bio Farma, Indonesia)
Co-chair : Parag Nagakar (Serum Institute of India)
Secretary : Sandra O Cho (Instituto Butantan, Brazil)

Members :
1. Indian Immunologicals, India
2. Panacea, India
3. SII, India
4. BioE, India
5. Pasteur Institute, India
6. Zhifei, China
7. Bravovax, China
8. BCHT, China
9. Innovax, China
10. CNBG, China
11. St Petersburg Scientific Research Institute of Vaccines and Sera, Russia
12. Biomanguinhos, Brazil
13. Singernium, Argentina
14. Bionet Asia, Thailand
DCVMN COVID-19 Committee

• First meeting held: June 19th 2020
• Meetings held triweekly: per June 10th 2021 monthly every second Thursday
• Sub-committees:
  • Clinical trials: Raches Ella (Lead) – Bharat Biotech
  • Partnerships: Yuri Vasiliev (Lead) – St Petersburg Scientific Research Institute of Vaccines and Sera
  • Replacement: Apoorv Kumar – Bharat Biotech
  • Quality Control: Sunil Gairola (Lead) – Serum Institute of India
Meeting agenda:
Routine:
- Epidemiological updates
- Updates on total vaccine doses administered
- Partnership updates
- Updates on CEPI initiatives
- Reports from sub committees
Others:
- Joint meeting with Regulatory Systems Working Group (Feb 18th 2021)
- Presentations from DCVMN members
- Group discussion with invited speaker
- Webinars
## DCVMN COVID Committee

### Presentations by DCVMN members

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Date of Presentation</th>
<th>Presentation topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Weining Meng</td>
<td>SINOVAC, China</td>
<td>June 10&lt;sup&gt;th&lt;/sup&gt; 2021</td>
<td>Clinical development of Sinovac COVID-19 vaccine</td>
</tr>
<tr>
<td>Dr. Sameer Naik</td>
<td>Serum Institute of India</td>
<td>Feb 10&lt;sup&gt;th&lt;/sup&gt; 2022</td>
<td>Understanding COVID-19 vaccines – challenges ahead</td>
</tr>
<tr>
<td>Dr. Gecilmara Salviato</td>
<td>Butantan, Brazil</td>
<td>March 10&lt;sup&gt;th&lt;/sup&gt; 2022</td>
<td>Booster dose vaccines</td>
</tr>
<tr>
<td>Dr. Andrew Wong</td>
<td>Walvax, China</td>
<td>April 14&lt;sup&gt;th&lt;/sup&gt;, 2022</td>
<td>COVID-19 vaccine candidates in mRNA platform</td>
</tr>
<tr>
<td>Dr. Parag Nagarkar</td>
<td>Serum Institute of India</td>
<td>June 8&lt;sup&gt;th&lt;/sup&gt; 2022</td>
<td>WHO EUL procedure – the challenges</td>
</tr>
</tbody>
</table>

### Presentations by invited speakers

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Date of Presentation</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Jakob Cramer</td>
<td>CEPI</td>
<td>Dec 3&lt;sup&gt;rd&lt;/sup&gt;, 2020</td>
<td>Webinar: An overview of COVID vaccine clinical trial results &amp; some challenges</td>
</tr>
<tr>
<td>Dr Matthew Downham</td>
<td>CEPI</td>
<td>Dec 9&lt;sup&gt;th&lt;/sup&gt;, 2021</td>
<td>Scenarios on COVID variants – the challenges</td>
</tr>
<tr>
<td>Dr Matt Linley</td>
<td>Airfinity</td>
<td>Jan 25&lt;sup&gt;th&lt;/sup&gt;, 2022</td>
<td>Webinar: Dynamic demand forecasting for COVID-19 vaccines</td>
</tr>
</tbody>
</table>
Participation of DCVMN members in CEPI’s initiatives

CMC platform protocol templates Working Groups

**Objective**: Build CMC platform protocol templates that are “pre-approved”/pre-agreed by worldwide regulators.

**Aim**: To streamline and accelerate vaccine development and to allow quicker access
- Ready-to-use tool based on agreed baseline and understanding

**Two areas**: 1) comparability and 2) manufacturing process validation

**First draft**: Feb 2023

**Industry participants**

1. **DCVMN**
   - Bio Farma
   - Biological E
   - Bio–Manguinhos / Fiocruz
   - BioVac
   - CanSino BIO
   - Instituto Butantan
   - Dohme (MSD)
   - Institut Pasteur Dakar
   - Sinergium Biotech
   - Walvax

2. **Non DCVMN**
   - Astra Zeneca
   - CureVac
   - GlaxoSmithKline
   - Innovative Biotech Nigeria
   - Johnson & Johnson – Janssen
   - Merck Sharp and
   - Quantoom Bioscience
   - Sanofi
   - Seqirus
   - Touchlight

**Enabling sciences**

- Paul Kristiansen (CEPI) & (BMGF or WHO, TBC)
- IFPMA (Gert Schepers/Inj), BMGF (TBC), CEPI Task Force Leads (Carolyn Clark and Valentina Bernasconi), CEPI regulatory (Deb Yeskey/Svein Rune Andersen), NIH/ACTIV (TBC), WHO (Ivana Krezevic), DCVMN (Weiying Meng/Sinovac)

**Clinical Development and Operations**

- Jakob Cramer (CEPI) & Peter Dull (BMGF)
- NIH/NAID (Hilary Marston), IFPMA (Thomas Breuer/GSK and Stephen Lockhart/Pfizer), DCVMN (Ricardo Palacios Gomes/Butantan Institute), Robert Chen (SPEAC/BC), Statistics, CEPI Epi (Gabrielle Breugelmans), CEPI regulatory (Deb Yeskey/Svein Rune Andersen), WHO (Ana Mata Henao Restrepo), LSHTM (Peter Smith), PATH (David Kaslow)

**Manufacturing**

- Ingrid Kromann/Nicolai Havelange (CEPI) & David Robinson (BMGF)
- IFPMA (Norio Tamura/Shionogi, Mike Thiem/Meck, Mike King), DCVMN (Adriansjah Azhari/ Biofarma Indonesia), WHO (Carmen Rodriguez Hernandez, Ivana Krezevic), Jim Robinson (CEPI CMC-SM), CEPI regulatory (Deb Yeskey/Svein Rune Andersen), Gavi (Dominique Maugears)

**Regulatory support**

- Deb Yeskey/ Svein Rune Andersen (CEPI), WHO & regulators
- Emer Cooke (WHO), Marion Guerri (FDA), Marco Cavaleri (EMA), David John Wood (WHO) & other regulators TBC

Information courtesy of CEPI
Thank You